SCHEMBL1264494

SCHEMBL1264494

NC(F)c1cc2ccccc2oc1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.56
POLB P06746 1/20 0.56
HPGD P15428 5/20 0.51
TYR P14679 1/20 0.51
DAO P14920 1/20 0.51
AKR1B1 P15121 1/20 0.51
CA12 O43570 3/20 0.50
CA9 Q16790 3/20 0.50
CA1 P00915 2/20 0.50
CA2 P00918 1/20 0.50
KDM4E B2RXH2 7/20 0.49
ALDH1A1 P00352 7/20 0.49
MAOB P27338 6/20 0.49
RAB9A P51151 4/20 0.49
NCOA1 Q15788 1/20 0.47
NCOA3 Q9Y6Q9 1/20 0.47
CA3 P07451 1/20 0.47
TSHR P16473 1/20 0.47
CA4 P22748 1/20 0.47
CA6 P23280 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL620973 0.86 HPGD (0.55) SMN1; SMN2POLBHPGDTYRDAO
SCHEMBL15736793 0.80 SMN1; SMN2 (0.53) SMN1; SMN2POLBHPGDTYRDAO
SCHEMBL11881581 0.79 MAOB (0.55) SMN1; SMN2POLBHPGDTYRDAO
SCHEMBL7142288 0.79 SMN1; SMN2 (0.51) SMN1; SMN2POLBHPGDTYRDAO
SCHEMBL12456653 0.79 HPGD (0.55) SMN1; SMN2POLBHPGDTYRDAO
SCHEMBL1568299 0.79 HPGD (0.59) SMN1; SMN2POLBHPGDTYRDAO
SCHEMBL30493818 0.79 HPGD (0.55) SMN1; SMN2POLBHPGDTYRDAO
SCHEMBL19127755 0.76 HPGD (0.56) SMN1; SMN2POLBHPGDTYRDAO
SCHEMBL28004016 0.73 HPGD (0.49) SMN1; SMN2POLBHPGDTYRDAO
SCHEMBL7143389 0.72 HPGD (0.51) SMN1; SMN2POLBHPGDTYRDAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7879574-B2 Folded peptide backbone each end of which is conjugated to a fluorophore, which when cleaved as by digestion with a protease, the fluorophores provide high intensity signals; histology ONCOIMMUNIN, INC. (US) 2011-02-01 US disclosed
US-20090325168-A1 HOMO-DOUBLY LABELED COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES ONCOIMMUNIN, INC. (US) 2009-12-31 US disclosed
EP-0988394-B1 COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES AND METHODS OF USE THEREOF ONCOIMMUNIN INC (US) 2009-12-30 EP disclosed
US-7541143-B2 Homo-doubly labeled compositions for the detection of enzyme activity in biological samples ONCOIMMUNIN, INC. (US) 2009-06-02 US disclosed
US-20080199898-A1 COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES AND METHODS OF USE THEREOF ONCOIMMUNIN, INC. (US) 2008-08-21 US disclosed
US-7312302-B2 Compositions for the detection of enzyme activity in biological samples and methods of use thereof ONCOLMMUNIN, INC. (US) 2007-12-25 US disclosed
EP-1214445-A4 COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES AND METHODS OF USE THEREOF ONCOIMMUNIN INC (US) 2007-01-24 EP disclosed
US-6936687-B1 Compositions for the detection of enzyme activity in biological samples and methods of use thereof ONCO IMMUNIN, INC. (US) 2005-08-30 US disclosed
US-20050158766-A1 Homo-doubly labeled compositions for the detection of enzyme activity in biological samples ONCOLMMUNIN, INC. 2005-07-21 US disclosed
US-6893868-B2 Homo-doubly labeled compositions for the detection of enzyme activity in biological samples ONCO IMMUNIN, INC. (US) 2005-05-17 US disclosed
US-20030207264-A1 Homo-doubly labeled compositions for the detection of enzyme activity in biological samples ONCOLMMUNIN, INC. 2003-11-06 US disclosed
EP-1356084-A2 HOMO-DOUBLY LABELED COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES ONCOIMMUNIN, INC. (US) 2003-10-29 EP disclosed
EP-0988394-A4 COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES AND METHODS OF USE THEREOF ONCOIMMUNIN INC (US) 2003-04-23 EP disclosed
WO-2002061038-A9 HOMO-DOUBLY LABELED COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES ONCOIMMUNIN INC (US) 2002-11-28 WO disclosed
WO-2002061038-A2 HOMO-DOUBLY LABELED COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES ONCOIMMUNIN, INC. (US) 2002-08-08 WO disclosed
EP-1214445-A1 COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES AND METHODS OF USE THEREOF ONCOIMMUNIN, INC. (US) 2002-06-19 EP disclosed
WO-2001018238-A1 COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES AND METHODS OF USE THEREOF ONCOIMMUNIN, INC. (US) 2001-03-15 WO disclosed
EP-0988394-A1 COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES AND METHODS OF USE THEREOF ONCOIMMUNIN, INC. (US) 2000-03-29 EP disclosed
US-6037137-A FLUORESCENT COMPOUND FOR SCREENING CLEAVING ACTIVITY AND STRUCTURAL CHANGES OF ENZYMATIC PROTEINS ONCOIMMUNIN, INC. (US) 2000-03-14 US disclosed
WO-1998037226-A1 COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES AND METHODS OF USE THEREOF ONCOIMMUNIN, INC. (US) 1998-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207264-A1 Homo-doubly labeled compositions for the detection of enzyme activity in biological samples DNTT, HMBS, WRN SMN1; SMN2 3740/4885POLB 285/4885HPGD 272/4885
US-20050158766-A1 Homo-doubly labeled compositions for the detection of enzyme activity in biological samples DNTT, WRN, HMBS SMN1; SMN2 3666/4885POLB 258/4885HPGD 315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.